© 2018 by BioSight Ltd.

  • LinkedIn Social Icon

Clinical Advisory Board

Jacob M. Rowe, MD Chairman

Dr. Rowe is former Chief, Department of Hematology and Bone Marrow Transplantation at Rambam Medical Center and Dresner Professor of Hemato-oncology, Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, in Haifa, Israel. He is also Adjunct Professor of Medicine in the Department of Medicine at Northwestern University in Chicago, Illinois. Dr. Rowe received a Bachelor of Medicine degree from the University College Hospital Medical School in London and subsequently trained in London, Israel, and the United States. Dr. Rowe’s work focuses on the development of new treatment modalities for patients with hematologic malignancies. Dr. Rowe is Editor-in-Chief of Baillieres Best Practice & Research: Clinical Hematology, Co-Editor of Blood Reviews, and Section Editor of Leukemia. He is also on the editorial boards of the American Journal of Hematology, Blood, Clinical Leukemia, and Leukemia Research. He has chaired 5 and currently is chairing 2 Eastern Cooperative Oncology Group (ECOG) clinical studies. Among other organizations, Dr. Rowe is a fellow of the American College of Physicians and a member of the American Society of Hematology, American Society of Clinical Oncology, European Bone Marrow Transplant Group, and National Oncology Council, Israel. Dr. Rowe has presented more than 
230 abstracts at major national and international meetings and has published more than 240 journal articles and book chapters.

Martin S. Tallman, MD

Dr.  Tallman is Chief, Leukemia Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York, USA.   He is a diplomate of the American Board of Internal Medicine with sub-specialty certification in the areas of hematology and medical oncology.  He served as Chair of the Leukemia Committee of the Eastern Cooperative Oncology Group for 16 years.  

Dr. Tallman is a member of numerous committees of national, regional, and international professional societies involved in the study and treatment of cancer, including the American Society of Hematology, American Society of Clinical Oncology, the Eastern Cooperative Oncology Group, the International Society of Thrombosis and Haemostasis, and the American Association for Cancer Research.  He serves as Co-Chair of the on the Acute Myeloid Leukemia Panel of the National Comprehensive Cancer Network (NCCN).  He is a fellow of the American College of Physicians. Dr. Tallman recently completed two terms as an Associate Editor of Blood.  He is a reviewer for many professional publications.

Dr. Tallman received his bachelor’s degree in Science at the University of Michigan in Ann Arbor, Michigan, USA and his medical degree at Finch University of Health Sciences/The Chicago Medical School in Chicago, Illinois, USA. 

 

Elihu H. Estey, MD

Dr. Estey is a Professor of Medicine at the Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA. He is an expert in treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with 38 years of active clinical practice with AML patients. Dr. Estey published over 700 articles on hematologic malignancies, the majority specifically in AML, and is an extensive reviewer of AML publications (Blood and JCO) and current Associate Editor of Leukemia.

Dr. Estey serves as a Member and Director of AML Clinical Research (non-transplant) Clinical Research Division at the Fred Hutchinson Cancer Research Center in Seattle, and on the European Leukemia Net (ELN) guidelines committee for AML. He formerly served as an advisor for AML studies to the Oncology Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration, as well as a mentor for many physicians who have risen to prominence in AML.

Jeffrey E. Lancet, MD

Dr. Lancet is a hematologist at Moffitt Cancer Center and the Department Chair of Malignant Hematology.  He focuses his clinical practice in acute leukemias and myelodysplastic syndromes.  He also provides consultation for other hematologic malignancies.  As a clinical investigator, he has written, authored and published several early phase clinical trials utilizing novel therapies for these diseases, and currently serves as the principal investigator or many ongoing trials.  Within the field of acute leukemias, he has worked extensively with the National Cancer Institute, the Southwest Oncology Group, and the pharmaceutical industry.  Dr. Lancet was a recipient of the NCI-ASCO Clinical Investigator Team Leadership Award in 2010.

 

Tsila Zuckerman, MD

Dr. Zuckerman is the Head of the Bone Marrow Transplantation Unit at Rambam Campus, Technion, Haifa, Israel. Dr. Zuckerman received her MD degree from the Faculty of Medicine of the Technion-Israel Institute of Technology. She completed Fellowships in Internal Medicine at the Carmel Medical Center, and in Hematology and Bone Marrow Transplantation at the University of Southern California, USA.

Dr. Zuckerman serves as coordinator of the Integrative Course in Hemato-Oncology at the Faculty of Medicine of the Technion. She is co-author of about 20 scientific articles, published in the leading international journals in the field of hematology, and is a presenter at major national and international meetings.   Her main research interests are the correlation between hepatitis C virus and development of lymphoma; complications of bone marrow transplantation including Veno-Occlusive Disease (VOD) and infections; and minimal residual disease in leukemia patients.

BIOSIGHT logo .png